Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background Burn patients often face a high risk of acute kidney injury (AKI) after severe burn injuries, meanwhile epigallocatechin-3-gallate (EGCG) has been proven to be effective in alleviating organ injury.Methods This study used the classical burn model in rats.Thirty model rats were randomly divided into a Burn group, a Burn + placebo group, a Burn + EGCG (50 mg/kg) group, and ten non-model rats as Sham group.The urinary excretion of the rats was subsequently monitored for a period of 48 h.After 48 h of different treatments, rat serum and kidneys were taken for the further verification.The efficacy of EGCG was assessed in pathological sections, biochemical indexes, and at the molecular level.Results Pathological sections were compared between the Burn group and Burn + placebo group.The rats in the Burn + EGCG group had less kidney damage.Moreover, the EGCG group maintained significantly elevated urine volumes, biochemical indexes manifested that EGCG could reduce serum creatinine (Cr) and neutrophil gelatinase-associated lipocalin (NGAL) level and inhibit the oxidation-related enzyme malondialdehyde (MDA) level, meanwhile the superoxide dismutase (SOD) level was increased.The molecular level showed that EGCG significantly reduced the mRNA expression levels of the inflammation-related molecules interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α).Conclusion The research indicated that EGCG had an alleviating effect on kidney injury in severely burned rats, and its alleviating effects were related to improving kidney functions, alleviating oxidative stress, and inhibiting the expression of inflammatory factors.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022
- Date Crossref
- 25/10/2023
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Kyoto University Department of Nephrology pays non établi dans la noticeUniversité ou école supérieure
-
Juntendo University pays non établi dans la noticeUniversité ou école supérieure
-
University of Tsukuba pays non établi dans la noticeUniversité ou école supérieure
-
Nagoya University Hospital Department of Clinical Oncology and Chemotherapy pays non établi dans la noticeÉtablissement de santé
-
Ashiya University pays non établi dans la noticeUniversité ou école supérieure
-
University of Tokyo Hospital Department of Emergency and Critical Care Medicine pays non établi dans la noticeÉtablissement de santé
-
Aichi Cancer Center pays non établi dans la noticeÉtablissement de santé
-
Tokyo Women's Medical University Department of Blood Purification pays non établi dans la noticeUniversité ou école supérieure
-
Anjo Kosei Hospital Department of Respiratory Medicine pays non établi dans la noticeÉtablissement de santé
-
Shiga University of Medical Science Department of Pediatrics pays non établi dans la noticeUniversité ou école supérieure
-
International University of Health and Welfare Department of Renal and Urologic Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Kitasato University Department of Pediatrics pays non établi dans la noticeUniversité ou école supérieure
Department of Nephrology — Kyoto University, Juntendo University et University of Tsukuba, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.